Timbetasin - RegeneRx Biopharmaceuticals

Drug Profile

Timbetasin - RegeneRx Biopharmaceuticals

Alternative Names: Fx peptide; GBT-201; RGN-137; RGN-259; RGN-352; RGN-457; TB4; TB4 16-38; Thymosin B4; Thymosin beta 4-16-38; Thymosin beta-4; Tβ4

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Chonbuk National University; Defiante Farmaceutica; RegeneRx Biopharmaceuticals; sigma-tau SpA; The George Washington University of Washington, D.C.; United States Army Medical Research Institute of Chemical Defense; Wayne State University; Zhejiang University
  • Class Anti-inflammatories; Eye disorder therapies; Heart failure therapies; Neuroprotectants; Peptide hormones; Proteins; Skin disorder therapies; Thymus hormones
  • Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Heat-shock protein modulators; MicroRNA modulators; Nerve growth factor stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Epidermolysis bullosa
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dry eyes; Keratitis
  • Phase II Epidermolysis bullosa
  • Phase I Multiple sclerosis; Myocardial infarction
  • Preclinical Brain injuries; Burns; Diabetic neuropathies; Musculoskeletal disorders; Pulmonary arterial hypertension; Stroke
  • No development reported Eye-Disorders; Pressure ulcer; Varicose ulcer
  • Discontinued Alopecia; Bronchiectasis; Cystic fibrosis; Diabetic foot ulcer; Diabetic retinopathy; Septic shock

Most Recent Events

  • 06 Sep 2018 GtreeBNT plans an open phase III trial for Epidermolysis bullosa in USA in 2018
  • 02 Aug 2018 Lenus Therapeutics (a subsidiary of GtreeBNT) plans a phase II trial for Epidermolysis bullosa (In children, In adolescents, In adults), in November 2018 (NCT03578029)
  • 09 Apr 2018 ReGenTree plans the pivotal phase III ARISE-3 trial for Dry eyes in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top